Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors

Richard Kefford, Wilson H. Miller, Daniel Shao-Weng Tan, Ryan J. Sullivan, Georgina Long, Rodrigo Dienstmann, Wai Meng David Tai, Keith Flaherty, Simone Stutvoet, Karl Maria Schumacher, Simon Wandel, Laure A. De Parseval, Josep Tabernero

Research output: Contribution to journalMeeting abstract

Fingerprint

Dive into the research topics of 'Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences